Excellent article on IBD, states 19 generics under development, 2 filed, one NDA in phase II trials, 15 NDA studies expected to be in progress or filed by third quarter.
Distribution business going "gangbusters", topping 8,000 customers in the distribution business, Prilosec filing, litigation issues in favor of company, expecting to turn profitable next quarter, Watson's 18% stake in the company, expects to establish an international presence etc. etc.
Basically as I stated before, this stock has a full tank of gas! |